Newsroom

Newsroom

Presenting the Future Home of Tevogen Bio

Tevogen Bio is pleased to finalize the design of its state-of-the-art, eco-friendly global headquarters in New Jersey. This facility will serve as the company’s central hub for research and development, manufacturing, and distribution of its investigational T cell therapies for COVID-19, other viral infections and oncology. The 160-thousand square foot facility will bring nearly 1,800 life sciences jobs to New Jersey, leveraging the state’s rich history and support structure for medical innovation. The headquarters will be powered, in part, by renewable energy based on solar and other environmentally-friendly technologies. Congratulations to our team of visionary architects and lab engineers!

Latest News

Tevogen Bio to Present Preclinical Data of TVGN-489, its Investigational Allogeneic Cytotoxic T Cell Therapy for COVID-19, at the 2021 Annual Meeting of American Association of Immunologists

Businesswire – April 12th, 2021


Tevogen CEO Ryan Saadi, MD, MPH, sat down with Cell & Gene Editor-In-Chief Erin Harris to discuss why T Cell therapy could be a potential game changer for COVID-19.

Cell & Gene – March 23rd, 2021


Tevogen Bio Announces Partnership With BioCentriq, New Jersey Innovation Institute’s Pioneering Cell and Gene Therapy Center, to Enhance Tevogen’s Development Capacity of Its Proprietary Targeted T Cell Therapy For COVID-19

Businesswire – March 15th, 2021


Tevogen Bio Secures Funding from Team of Doctors to Support Clinical Trials of Its Investigational Curative T Cell Therapy for COVID-19

Newswire – January 25th, 2021


Tevogen Bio Announces IND Submitted to FDA for Clinical Trials of T Cell Treatment for COVID-19

Newswire – October 14th, 2020


Dr. Flomenberg discusses T Cell therapy for COVID-19 with 6ABC News.

6ABC – August 20th, 2020


Tevogen Bio Announces Partnership With Preeminent Scientist Professor Neal Flomenberg, M.D., to Investigate Proprietary T-Cell Therapy for Treatment of COVID-19 & Influenza

Newswire – August 10th, 2020


Tevogen Bio Announces Steps Toward a Proprietary T Cell Therapy for Treatment of COVID-19 & Development of Bivalent Vaccine for COVID-19 & Influenza

Newswire – July 15th, 2020

© 2021 Tevogen Bio. All Rights Reserved.